Cost-Effectiveness Of Culture-Based Versus Empirical Antibiotic Treatment For Hospitalized Adults With Community-Acquired Pneumonia In Indonesia: A Real-World Patient-Database Study

References

• Feldman C, Anderson R. Community-acquired pneumonia: still a major burden of disease. Curr Opin Crit Care. 2016;22(5):477–484. doi:10.1097/MCC.000000000000034027583588
   PubMedGoogle Scholar
• Bonafede MM, Suaya JA, Wilson KL, Mannino DM, Polsky D. Incidence and cost of CAP in a large working-age population. Am J Manag Care. 2012;18(7):380–387.22823532
   PubMed Web of Science ®Google Scholar
• Welte T, Torres A, Nathwani D. Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax. 2012;67(1):71–79. doi:10.1136/thx.2009.12950220729232
   PubMed Web of Science ®Google Scholar
• Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44(Suppl 2):S27–S72. doi:10.1086/51115917278083
   PubMed Web of Science ®Google Scholar
• Eccles S, Pincus C, Higgins B, et al. Diagnosis and management of community and hospital acquired pneumonia in adults: summary of NICE guidance. BMJ. 2014;349(December):1–5. doi:10.1136/bmj.g6722
   Web of Science ®Google Scholar
• Lim WS, Baudouin SV, George RC, et al. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax. 2009;64(Suppl 3):iii1–iii55. doi:10.1136/thx.2009.12143419783532
   PubMed Web of Science ®Google Scholar
• Martin M, Moore L, Quilici S, Decramer M, Simoens S. A cost-effectiveness analysis of antimicrobial treatment of community-acquired pneumonia taking into account resistance in Belgium. Curr Med Res Opin. 2008;24(3):737–751. doi:10.1185/030079908X27333618230196
   PubMed Web of Science ®Google Scholar
• Martin M, Quilici S, File T, Garau J, Kureishi A, Kubin M. Cost-effectiveness of empirical prescribing of antimicrobials in community-acquired pneumonia in three countries in the presence of resistance. J Antimicrob Chemother. 2007;59(5):977–989. doi:10.1093/jac/dkm03317395688
   PubMedGoogle Scholar
• Kuti JL, Capitano B, Nicolau DP. Cost-effective approaches to the treatment of community-acquired pneumonia in the era of resistance. Pharmacoeconomics. 2002;20(8):513–528. doi:10.2165/00019053-200220080-0000212109917
   PubMedGoogle Scholar
• Torres A, Lee N, Cilloniz C, Vila J, Van der Eerden M. Laboratory diagnosis of pneumonia in the molecular age. Eur Respir J. 2016;48(6):1764–1778. doi:10.1183/13993003.01144-201627811073
   PubMed Web of Science ®Google Scholar
• Lee JS, Primack BA, Mor MK, et al. Processes of care and outcomes for community-acquired pneumonia. Am J Med. 2011;124(12):1175.e9–1175.e17. doi:10.1016/j.amjmed.2011.05.029
   Web of Science ®Google Scholar
• Prina E, Ranzani OT, Torres A. Community-acquired pneumonia. Lancet (London, England). 2015;386(9998):1097–1108. doi:10.1016/S0140-6736(15)60733-4
   PubMed Web of Science ®Google Scholar
• Woodhead M. New guidelines for the management of adult lower respiratory tract infections. Eur Respir J. 2011;38(6):1250–1251. doi:10.1183/09031936.0010521122130759
   PubMedGoogle Scholar
• Indonesian Society of Respirology. Guideline for diagnosis and management of community pneumonia in Indonesia. Available from: https://www.scribd.com/doc/125419923/Pnemonia-Komuniti-Pdpi. Published 2003 Accessed 422, 2019.
   Google Scholar
• Ethical principles for medical research involving human subjects version 2013. 64th World Medical Association General Assembly, Fortaleza, Brazil, 10 2013 Available from: https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/. Accessed 711, 2019.
   Google Scholar
• UNFPA. Indonesia on the threshold of population ageing; 2014 Available from: https://indonesia.unfpa.org/sites/default/files/pub-pdf/BUKU_Monograph_No1_Ageing_03_Low-res.pdf.
   Google Scholar
• Aujesky D, Auble TE, Yealy DM, et al. Prospective comparison of three validated prediction rules for prognosis in community-acquired pneumonia. Am J Med. 2005;118(4):384–392. doi:10.1016/j.amjmed.2005.01.00615808136
   PubMed Web of Science ®Google Scholar
• The World Bank. Life expectancy at birth, total (years). Available from: https://data.worldbank.org/indicator/SP.DYN.LE00.IN?locations=ID. Published 2019 Accessed 422, 2019.
   Google Scholar
• Indonesian Health Technology Assessment Committee (InaHTAC), Ministry of Health of the Republic of Indonesia. Health Technology Assessment (HTA) Guideline. Available from: http://adphealth.org/upload/resource/FINAL_HTA_ENG_-1.pdf. Published 2017 Accessed 1123, 2019.
   Google Scholar
• Organization for Economic Cooperation and Development (OECD). Available from: https://data.oecd.org/conversion/exchange-rates.htm. Published 2018 Accessed April 22, 2019.
   Google Scholar
• Marseille E, Larson B, Kazi DS, Khan JG, Rosen S. Policy and Practice, Thresholds for the cost-effectiveness of interventions: alternative approaches. Bull World Health Organ. 2015;93(2):118-124. doi:10.2471/BLT.14.138206
   Web of Science ®Google Scholar
• Setiawan D, Dolk FC, Suwantika AA, Westra TA, WIlschut JC, Postma MJ. Cost-utility analysis of human papillomavirus vaccination and cervical screening on cervical cancer patient in Indonesia. Value Heal Reg Issues. 2016;9:84–92. doi:10.1016/j.vhri.2015.10.010
   PubMedGoogle Scholar
• The World Bank. GDP per capita (current US$). Available from: https://data.worldbank.org/indicator/ny.gdp.pcap.cd?end=2017&start=2016&year_high_desc=false. Published 2019 Accessed 422, 2019.
   Google Scholar
• Olasupo O, Xiao H, Brown JD. Relative clinical and cost burden of community-acquired pneumonia hospitalizations in older adults in the United States-a cross-sectional analysis. Vaccines. 2018;6:3. doi:10.3390/vaccines6030059
   Web of Science ®Google Scholar
• Konomura K, Nagai H, Akazawa M. Economic burden of community-acquired pneumonia among elderly patients: a Japanese perspective. Pneumonia (Nathan Qld). 2017;9:19. doi:10.1186/s41479-017-0042-129226070
   PubMedGoogle Scholar
• Choi MJ, Song JY, Noh JY, et al. Disease burden of hospitalized community-acquired pneumonia in South Korea: analysis based on age and underlying medical conditions. Medicine (Baltimore). 2017;96(44):e8429. doi:10.1097/MD.000000000000842929095281
   PubMed Web of Science ®Google Scholar
• Vissink CE, Huijts SM, de Wit GA, Bonten MJM, Mangen M-J-J. Hospitalization costs for community-acquired pneumonia in Dutch elderly: an observational study. BMC Infect Dis. 2016;16:466. doi:10.1186/s12879-016-1783-927589847
   PubMed Web of Science ®Google Scholar
• Lee JY, Yoo CG, Kim H-J, Jung KS, Yoo KH. Disease burden of pneumonia in Korean adults aged over 50 years stratified by age and underlying diseases. Korean J Intern Med. 2014;29(6):764–773. doi:10.3904/kjim.2014.29.6.76425378975
   PubMedGoogle Scholar
• Torres A, Peetermans WE, Viegi G, Blasi F. Risk factors for community-acquired pneumonia in adults in Europe: a literature review. Thorax. 2013;68(11):1057–1065. doi:10.1136/thoraxjnl-2013-20428224130229
   PubMed Web of Science ®Google Scholar
• Cilloniz C, Polverino E, Ewig S, et al. Impact of age and comorbidity on cause and outcome in community-acquired pneumonia. Chest. 2013;144(3):999–1007. doi:10.1378/chest.13-006223670047
   PubMed Web of Science ®Google Scholar
• Falagas ME, Mourtzoukou EG, Vardakas KZ. Sex differences in the incidence and severity of respiratory tract infections. Respir Med. 2007;101(9):1845–1863. doi:10.1016/j.rmed.2007.04.01117544265
   PubMed Web of Science ®Google Scholar
• Gutierrez F, Masia M, Mirete C, et al. The influence of age and gender on the population-based incidence of community-acquired pneumonia caused by different microbial pathogens. J Infect. 2006;53(3):166–174. doi:10.1016/j.jinf.2005.11.00616375972
   PubMedGoogle Scholar
• Rivero-Calle I, Pardo-Seco J, Aldaz P, et al. Incidence and risk factor prevalence of community-acquired pneumonia in adults in primary care in Spain (NEUMO-ES-RISK project). BMC Infect Dis. 2016;16(1):645. doi:10.1186/s12879-016-1974-427821085
   PubMedGoogle Scholar
• Egger ME, Myers JA, Arnold FW, Pass LA, Ramirez JA, Brock GN. Cost effectiveness of adherence to IDSA/ATS guidelines in elderly patients hospitalized for community-aquired pneumonia. BMC Med Inform Decis Mak. 2016;16:34. doi:10.1186/s12911-016-0270-y26976388
   PubMed Web of Science ®Google Scholar
• Kateel R, Adhikari P, Rajm S. Cost and antibiotic utilization of pneumonia patients in intensive care unit. J Appl Pharm. 2016;6(02):87–90. doi:10.7324/JAPS.2016.60212
   Google Scholar
• García-Vázquez E, Marcos MA, Mensa J, et al. Assessment of the usefulness of sputum culture for diagnosis of community-acquired pneumonia using the PORT predictive scoring system. Arch Intern Med. 2004;164(16):1807–1811. doi:10.1001/archinte.164.16.180715364677
   PubMedGoogle Scholar
• Afshar N, Tabas J, Afshar K, Silbergleit R. Blood cultures for community-acquired pneumonia: are they worthy of two quality measures? A systematic review. J Hosp Med. 2009;4(2):112–123. doi:10.1002/jhm.38219219920
   PubMedGoogle Scholar
• Metersky ML, Ma A, Bratzler DW, Houck PM. Predicting bacteremia in patients with community-acquired pneumonia. Am J Respir Crit Care Med. 2004;169(3):342–347. doi:10.1164/rccm.200309-1248OC14630621
   PubMed Web of Science ®Google Scholar
• Campbell SG, Marrie TJ, Anstey R, Dickinson G, Ackroyd-Stolarz S. The contribution of blood cultures to the clinical management of adult patients admitted to the hospital with community-acquired pneumonia: a prospective observational study. Chest. 2003;123(4):1142–1150. doi:10.1378/chest.123.4.114212684305
   PubMedGoogle Scholar
• Dik JH, Poelman R, Friedrich AW, Niesters HGM, Rossen JWA, Sinha B. Integrated Stewardship model comprising antimicrobial, infection prevention, and diagnostic stewardship (AID Stewardship). J Clin Microbiol. 2017;55(11):3306–3307. doi:10.1128/JCM.01283-1729066567
   PubMed Web of Science ®Google Scholar
• Dik J-WH, Hendrix R, Poelman R, et al. Measuring the impact of antimicrobial stewardship programs. Expert Rev Anti Infect Ther. 2016;14(6):569–575. doi:10.1080/14787210.2016.117806427077229
   PubMed Web of Science ®Google Scholar
• McAdam AJ. Reducing contamination of blood cultures: consider costs and clinical benefits. Clin Infect Dis. 2017;65(2):206–207. doi:10.1093/cid/cix30628379305
   PubMedGoogle Scholar
• Alahmadi YM, Aldeyab MA, McElnay JC, et al. Clinical and economic impact of contaminated blood cultures within the hospital setting. J Hosp Infect. 2011;77(3):233–236. doi:10.1016/j.jhin.2010.09.03321216032
   PubMed Web of Science ®Google Scholar
• Altun O, Botero-Kleiven S, Carlsson S, Ullberg M, Ozenci V. Rapid identification of bacteria from positive blood culture bottles by MALDI-TOF MS following short-term incubation on solid media. J Med Microbiol. 2015;64(11):1346–1352. doi:10.1099/jmm.0.00016826361761
   PubMedGoogle Scholar
• Food and Drug Administration. Medical devices; immunology and microbiology devices; classification of multiplex nucleic acid assay for identification of microorganisms and resistance markers from positive blood cultures. Final order. Fed Regist. 2015;80(101):30153–30155.26030936
   PubMedGoogle Scholar
• Heimann SM, Cruz Aguilar MR, Mellinghof S, Vehreschild MJGT. Economic burden and cost-effective management of Clostridium difficile infections. Med Mal Infect. 2018;48(1):23–29. doi:10.1016/j.medmal.2017.10.01029336929
   PubMed Web of Science ®Google Scholar